Literature DB >> 16847433

V3 versican isoform expression has a dual role in human melanoma tumor growth and metastasis.

Laia Miquel-Serra1, Montserrat Serra, Daniel Hernández, Clelia Domenzain, María José Docampo, Rosa M Rabanal, Inés de Torres, Thomas N Wight, Angels Fabra, Anna Bassols.   

Abstract

Versican is a large chondroitin sulfate proteoglycan produced by several tumor cell types, including malignant melanoma, which exists as four different splice variants. The presence of versican in the extracellular matrix plays a role in tumor cell growth, adhesion and migration, which could be altered by altering the ratio between versican isoforms. We have previously shown that overexpression of the V3 isoform of versican in human melanoma cell lines markedly reduces cell growth in vitro and in vivo, since V3-overexpressing (LV3SN) cultured cells as well as primary tumors arising from these cells grow slower than their vector-only counterparts (LXSN). In the present work, we have extended these observations to demonstrate that the delayed cell growth is due to multiple events since differences in proliferative index as well as in apoptosis are observed in LV3SN cells and tumors compared to LXSN. For example, LV3SN melanoma cells exhibit delayed activation of MAPK in response to EGF, we have also characterized further the primary tumors originated in nude mice from V3-transduced melanoma cells to determine if other events affect the V3 tumor phenotype. For example, hyaluronan content of LV3SN tumors was higher than in LXSN tumors, whereas other related matrix components and vascularization were unaffected. Furthermore, lung metastasis in nude mice occurred only in animals carrying LV3SN tumors, indicating a dual role for this molecule, both as an inhibitor of tumor growth and a metastasis inductor.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16847433     DOI: 10.1038/labinvest.3700449

Source DB:  PubMed          Journal:  Lab Invest        ISSN: 0023-6837            Impact factor:   5.662


  31 in total

1.  RhoGDI2 suppresses lung metastasis in mice by reducing tumor versican expression and macrophage infiltration.

Authors:  Neveen Said; Marta Sanchez-Carbayo; Steven C Smith; Dan Theodorescu
Journal:  J Clin Invest       Date:  2012-03-12       Impact factor: 14.808

2.  V3 versican isoform alters the behavior of human melanoma cells by interfering with CD44/ErbB-dependent signaling.

Authors:  Daniel Hernández; Laia Miquel-Serra; María-José Docampo; Anna Marco-Ramell; Jennifer Cabrera; Angels Fabra; Anna Bassols
Journal:  J Biol Chem       Date:  2010-11-15       Impact factor: 5.157

3.  Expression of V3 Versican by Rat Arterial Smooth Muscle Cells Promotes Differentiated and Anti-inflammatory Phenotypes.

Authors:  Inkyung Kang; Jeremy L Barth; Erin P Sproul; Dong Won Yoon; Gail A Workman; Kathleen R Braun; W Scott Argraves; Thomas N Wight
Journal:  J Biol Chem       Date:  2015-07-07       Impact factor: 5.157

4.  Versican isoform V1 regulates proliferation and migration in high-grade gliomas.

Authors:  Julia Onken; Sylvia Moeckel; Petra Leukel; Verena Leidgens; Fusun Baumann; Ulrich Bogdahn; Arabel Vollmann-Zwerenz; Peter Hau
Journal:  J Neurooncol       Date:  2014-07-27       Impact factor: 4.130

Review 5.  Versican and the regulation of cell phenotype in disease.

Authors:  Thomas N Wight; Michael G Kinsella; Stephen P Evanko; Susan Potter-Perigo; Mervyn J Merrilees
Journal:  Biochim Biophys Acta       Date:  2014-01-05

6.  Targeting of stromal versican by miR-144/199 inhibits multiple myeloma by downregulating FAK/STAT3 signalling.

Authors:  Nidhi Gupta; Raman Kumar; Tulika Seth; Bhavuk Garg; Alpana Sharma
Journal:  RNA Biol       Date:  2019-09-29       Impact factor: 4.652

Review 7.  Proteoglycans as Immunomodulators of the Innate Immune Response to Lung Infection.

Authors:  Inkyung Kang; Mary Y Chang; Thomas N Wight; Charles W Frevert
Journal:  J Histochem Cytochem       Date:  2018-01-12       Impact factor: 2.479

8.  Expression of Different Isoforms of Versican During the Development of Mouse Mandibular First Molars.

Authors:  Fangfang Xu; Wenping Cai; Weiting Chen; Lefeng Li; Xuyan Li; Beizhan Jiang
Journal:  J Histochem Cytochem       Date:  2019-04-29       Impact factor: 2.479

Review 9.  Versican and Versican-matrikines in Cancer Progression, Inflammation, and Immunity.

Authors:  Athanasios Papadas; Garrett Arauz; Alexander Cicala; Joshua Wiesner; Fotis Asimakopoulos
Journal:  J Histochem Cytochem       Date:  2020-07-06       Impact factor: 2.479

10.  Alteration of chondroitin sulfate composition on proteoglycan produced by knock-in mouse embryonic fibroblasts whose versican lacks the A subdomain.

Authors:  Keittisak Suwan; Sonoko Hatano; Prachya Kongtawelert; Peraphan Pothacharoen; Hideto Watanabe
Journal:  Ups J Med Sci       Date:  2009       Impact factor: 2.384

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.